scispace - formally typeset
U

Ulrike Bernauer

Researcher at Federal Institute for Risk Assessment

Publications -  64
Citations -  1448

Ulrike Bernauer is an academic researcher from Federal Institute for Risk Assessment. The author has contributed to research in topics: Sun tanning & Population. The author has an hindex of 16, co-authored 61 publications receiving 1289 citations.

Papers
More filters
Journal ArticleDOI

Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010

TL;DR: In this paper, Adler et al. present a survey of the authors' work in the field of bioinformatics, including the following authors:Sarah AdlerDavid BasketterStuart CretonOlavi PelkonenJan van BenthemValerie Zuang • Klaus Ejner AndersenAlexandre Angers-LoustauAynur AptulaAnna Bal-PriceEmilio Benfenati • Ulrike BernauerJos BessemsFrederic Y. BoisAlan BoobisEsther BrandonSusanne Bremer • Thomas
Journal ArticleDOI

Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches

TL;DR: In this article, a Physiologically Based Toxicokinetic Modeling (PBTK) is proposed to estimate the range of target organ doses that can be expected from realistic human external exposure scenarios.
Journal ArticleDOI

The safety of medical devices containing DEHP plasticized PVC or other plasticizers on neonates and other groups possibly at risk (2015 update).

TL;DR: This paper presents a meta-analysis of the literature on determinants of infectious disease and its applications to infectious disease treatment and its implications for medicine and public health.
Journal ArticleDOI

Human CYP2E1 mediates the formation of glycidamide from acrylamide

TL;DR: It is concluded that AA is metabolized to GA primarily by CYP2E1, and the involvement, for the first time, of human CYP 2E1 in the formation of GA from AA is described.
Journal ArticleDOI

Extrahepatic metabolism at the body's internal–external interfaces

TL;DR: This review summarizes the knowledge on the expression of phase I and phase II XMEs and transporters in extrahepatic tissues at the body's internal–external interfaces in the lung, kidney, bladder and skin.